Phase 3 program for Parkinson’s drug risvodetinib gets FDA review
Risvodetinib, an experimental oral small molecule Abli Therapeutics is developing for people with untreated Parkinson’s disease, may be…
Articles by Margarida Maia, PhD
Small molecule blocking cell death may be used in Parkinson’s
A small molecule that blocks the interaction between two proteins could help protect nerve cells from premature death in neurodegenerative…
Hillhurst gets $6.3M funding for HBI-002 clinical study
Hillhurst Biopharmaceuticals said it’s been awarded $6.3 million to fund a Phase 2a clinical study to test the efficacy of…
ANPD001 eases motor symptoms, early trial data show
The first three patients treated with ANPD001, a cell therapy for Parkinson’s disease, showed reduced motor symptoms and…
Study findings ‘lay foundation’ for targeted therapies in Parkinson’s
A small molecule called NK036 — which inhibits USP30, an enzyme that counters the removal of damaged mitochondria from nerve…
Walking to music helps Parkinson’s patients walk more: Study
Listening to rhythm-based cues while walking not only builds lasting walking habits, but also helps people with Parkinson’s disease…
Peptides prevent alpha-synuclein clumps seen in Parkinson’s in lab
Ring-shaped small proteins called macrocyclic peptides — originally developed to target proteins linked to diabetes and Alzheimer’s disease — have…
Brain inflammation linked to higher risk of dementia in Parkinson’s
Inflammation visible in brain scans of people in the early stages of Parkinson’s disease may serve as an early…
Affordable, vibrating glove may help patients regain motor control
Two undergraduate students from Rice University in Houston have designed an affordable, vibrating glove that they say lets patients feel…
Parkinson’s misdiagnoses in Finland illustrate need for better criteria
Nearly 1 in 8 people diagnosed with Parkinson’s disease in Finland within the past couple of decades were later…